Home » Newsletters » BioWorld Science

BioWorld Science

April 24, 2006

View Archived Issues

Leuprolide beneficial in phase II Alzheimer's disease study

Phase II studies show anemia correction with CERA in chronic kidney disease

Phase IIa study of LAB CGRP begins enrollment

Chimerix signs CRADA with U.S. Army for smallpox therapeutic CMX-001

Enrollment begins in phase III Bronchitol study

Vectura to work with Boehringer Ingelheim on dry powder inhaler

CEL-1000 shows adjuvant activity with malaria vaccines

ACP-103 increases slow wave sleep in clinical study

Pilot study of MM-093 in psoriasis completes enrollment

Bio-E-Gel NDA accepted for review

End of phase II testing of diquafosol in Asia triggers milestone payment

Enrollment completed in pivotal study of IL-Trap for CAPS

Stressgen to focus on reformulated HspE7

NIAID funds development of VivaGel for genital herpes

New evidence that selective M3 muscarinic antagonists can inhibit tumor growth

Feeding-suppressive properties of new orally active NPY Y5 antagonist

Antiangiogenic efficacy of a new multiple RTK inhibitor from Roche

Endocyte investigates folate-targeted cytotoxic anticancer drug in phase I study

Meditor begins phase II trial for MTR-104 in intradialytic hypotension

Yaz now available

Alteon and HaptoGuard to merge

Takeda and Lilly conclude U.S. Actos marketing collaboration

Pozen completes SPA for PN-200

European Commission approves Prograf for use in heart transplantation

Recent patents cover therapeutic agents for neurological disorders

Novel treatment options for endocrine-related disorders disclosed in recent patents

Therapeutic agents for cardiovascular disorders disclosed in recent patents

Dual muscarinic M3 receptor antagonists and PDE4 inhibitors potentially effective for COPD

Novel agent for the management of acute renal failure in sepsis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...